378 related articles for article (PubMed ID: 12046071)
21. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
22. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
23. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
24. [The anti-tumor effects of dendritic cells co-cultured with cytokine induced killer cells after chemotherapy].
Zhang S; Zhang SQ; Bai CX
Zhonghua Jie He He Hu Xi Za Zhi; 2004 May; 27(5):315-9. PubMed ID: 15196340
[TBL] [Abstract][Full Text] [Related]
25. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
26. [Induction of dendritic cells from intra-operative lost blood and their effects on CIK against liver cancer cells in vitro].
DU Z; Zhao XL; Gao YT; Wu CX; Wang YJ; Zhu ZY; Sun Q; Fang SC
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):759-63. PubMed ID: 19173806
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R; Guo T
Cancer Biother Radiopharm; 2010 Aug; 25(4):465-70. PubMed ID: 20701541
[TBL] [Abstract][Full Text] [Related]
28. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
29. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
30. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
31. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
32. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.
Wang P; Yu JP; Gao SY; An XM; Ren XB; Wang XG; Li WL
Cell Immunol; 2008; 253(1-2):59-65. PubMed ID: 18522858
[TBL] [Abstract][Full Text] [Related]
33. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
[TBL] [Abstract][Full Text] [Related]
34. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
35. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.
Yang CK; Huang CH; Hu CH; Fang JH; Chen TC; Lin YC; Lin CY
PLoS One; 2023; 18(1):e0280023. PubMed ID: 36598909
[TBL] [Abstract][Full Text] [Related]
37. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
38. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
39. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of cytokine-induced killer cells against human lung cancer.
Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
